_version_ 1783708603178287104
author Arulananda, Surein
O’Brien, Megan
Evangelista, Marco
Harris, Tiffany J.
Steinohrt, Nikita S.
Jenkins, Laura J.
Walkiewicz, Marzena
O’Donoghue, Robert J. J.
Poh, Ashleigh R.
Thapa, Bibhusal
Williams, David S.
Leong, Trishe
Mariadason, John M.
Li, Xia
Cebon, Jonathan
Lee, Erinna F.
John, Thomas
Fairlie, W. Douglas
author_facet Arulananda, Surein
O’Brien, Megan
Evangelista, Marco
Harris, Tiffany J.
Steinohrt, Nikita S.
Jenkins, Laura J.
Walkiewicz, Marzena
O’Donoghue, Robert J. J.
Poh, Ashleigh R.
Thapa, Bibhusal
Williams, David S.
Leong, Trishe
Mariadason, John M.
Li, Xia
Cebon, Jonathan
Lee, Erinna F.
John, Thomas
Fairlie, W. Douglas
author_sort Arulananda, Surein
collection PubMed
description
format Online
Article
Text
id pubmed-8206255
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-82062552021-07-01 Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma Arulananda, Surein O’Brien, Megan Evangelista, Marco Harris, Tiffany J. Steinohrt, Nikita S. Jenkins, Laura J. Walkiewicz, Marzena O’Donoghue, Robert J. J. Poh, Ashleigh R. Thapa, Bibhusal Williams, David S. Leong, Trishe Mariadason, John M. Li, Xia Cebon, Jonathan Lee, Erinna F. John, Thomas Fairlie, W. Douglas Cell Death Discov Correction Nature Publishing Group UK 2021-06-15 /pmc/articles/PMC8206255/ /pubmed/34131107 http://dx.doi.org/10.1038/s41420-020-00388-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Correction
Arulananda, Surein
O’Brien, Megan
Evangelista, Marco
Harris, Tiffany J.
Steinohrt, Nikita S.
Jenkins, Laura J.
Walkiewicz, Marzena
O’Donoghue, Robert J. J.
Poh, Ashleigh R.
Thapa, Bibhusal
Williams, David S.
Leong, Trishe
Mariadason, John M.
Li, Xia
Cebon, Jonathan
Lee, Erinna F.
John, Thomas
Fairlie, W. Douglas
Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
title Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
title_full Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
title_fullStr Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
title_full_unstemmed Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
title_short Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
title_sort correction: bcl-xl is an actionable target for treatment of malignant pleural mesothelioma
topic Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206255/
https://www.ncbi.nlm.nih.gov/pubmed/34131107
http://dx.doi.org/10.1038/s41420-020-00388-7
work_keys_str_mv AT arulanandasurein correctionbclxlisanactionabletargetfortreatmentofmalignantpleuralmesothelioma
AT obrienmegan correctionbclxlisanactionabletargetfortreatmentofmalignantpleuralmesothelioma
AT evangelistamarco correctionbclxlisanactionabletargetfortreatmentofmalignantpleuralmesothelioma
AT harristiffanyj correctionbclxlisanactionabletargetfortreatmentofmalignantpleuralmesothelioma
AT steinohrtnikitas correctionbclxlisanactionabletargetfortreatmentofmalignantpleuralmesothelioma
AT jenkinslauraj correctionbclxlisanactionabletargetfortreatmentofmalignantpleuralmesothelioma
AT walkiewiczmarzena correctionbclxlisanactionabletargetfortreatmentofmalignantpleuralmesothelioma
AT odonoghuerobertjj correctionbclxlisanactionabletargetfortreatmentofmalignantpleuralmesothelioma
AT pohashleighr correctionbclxlisanactionabletargetfortreatmentofmalignantpleuralmesothelioma
AT thapabibhusal correctionbclxlisanactionabletargetfortreatmentofmalignantpleuralmesothelioma
AT williamsdavids correctionbclxlisanactionabletargetfortreatmentofmalignantpleuralmesothelioma
AT leongtrishe correctionbclxlisanactionabletargetfortreatmentofmalignantpleuralmesothelioma
AT mariadasonjohnm correctionbclxlisanactionabletargetfortreatmentofmalignantpleuralmesothelioma
AT lixia correctionbclxlisanactionabletargetfortreatmentofmalignantpleuralmesothelioma
AT cebonjonathan correctionbclxlisanactionabletargetfortreatmentofmalignantpleuralmesothelioma
AT leeerinnaf correctionbclxlisanactionabletargetfortreatmentofmalignantpleuralmesothelioma
AT johnthomas correctionbclxlisanactionabletargetfortreatmentofmalignantpleuralmesothelioma
AT fairliewdouglas correctionbclxlisanactionabletargetfortreatmentofmalignantpleuralmesothelioma